Randomized Non Comparative Phase II Trial With Bevacizumab and Fotemustine in the Treatment of Recurrent Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Bevacizumab (Primary) ; Fotemustine
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Roche
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 27 Jan 2014 As per the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 23 May 2013 Planned end date changed from 1 Dec 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.